ImmunoPrecise Antibodies (IPA) Competitors $0.49 0.00 (-0.24%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.48 0.00 (-0.80%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. IZTC, OCX, ADAG, CRVO, CRBP, TCRX, IMAB, JMAC, INZY, and CRBUShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Invizyne Technologies (IZTC), OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), Corbus Pharmaceuticals (CRBP), TScan Therapeutics (TCRX), I-Mab (IMAB), Maxpro Capital Acquisition (JMAC), Inozyme Pharma (INZY), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Invizyne Technologies OncoCyte Adagene CervoMed Corbus Pharmaceuticals TScan Therapeutics I-Mab Maxpro Capital Acquisition Inozyme Pharma Caribou Biosciences ImmunoPrecise Antibodies (NASDAQ:IPA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations. Does the media prefer IPA or IZTC? In the previous week, ImmunoPrecise Antibodies had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for ImmunoPrecise Antibodies and 0 mentions for Invizyne Technologies. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score. Company Overall Sentiment ImmunoPrecise Antibodies Neutral Invizyne Technologies Neutral Does the MarketBeat Community believe in IPA or IZTC? ImmunoPrecise Antibodies received 15 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformImmunoPrecise AntibodiesOutperform Votes1593.75% Underperform Votes16.25%Invizyne TechnologiesN/AN/A Which has better earnings and valuation, IPA or IZTC? Invizyne Technologies has lower revenue, but higher earnings than ImmunoPrecise Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$24.00M0.93-$20.13M-$1.16-0.42Invizyne TechnologiesN/AN/AN/AN/AN/A Do insiders & institutionals believe in IPA or IZTC? 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is IPA or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. Invizyne Technologies' return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-114.50% -73.74% -42.68% Invizyne Technologies N/A N/A N/A Do analysts prefer IPA or IZTC? ImmunoPrecise Antibodies currently has a consensus price target of $4.00, indicating a potential upside of 718.16%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher probable upside, equities research analysts clearly believe ImmunoPrecise Antibodies is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryImmunoPrecise Antibodies beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.38M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.638.9226.7619.71Price / Sales0.93252.24389.94117.54Price / CashN/A65.8538.2534.62Price / Book0.536.466.804.50Net Income-$20.13M$143.98M$3.23B$248.18M7 Day Performance0.82%2.03%1.52%0.23%1 Month Performance12.39%4.11%10.04%12.39%1 Year Performance-58.57%-2.87%16.73%7.07% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.2462 of 5 stars$0.49-0.2%$4.00+718.2%-56.7%$22.38M$24.00M-0.6380News CoverageIZTCInvizyne TechnologiesN/A$13.01+4.0%N/AN/A$81.34MN/A0.00N/AOCXOncoCyte2.4132 of 5 stars$2.81-2.1%$4.42+57.2%+8.9%$80.36M$1.88M-0.64120Analyst ForecastGap DownADAGAdagene2.3111 of 5 stars$1.70+6.2%$8.00+370.9%-35.9%$80.04M$103,204.000.00260CRVOCervoMed3.3162 of 5 stars$9.10+7.2%$27.63+203.6%-56.2%$79.20M$7.14M-4.484Gap UpCRBPCorbus Pharmaceuticals4.5886 of 5 stars$7.16+11.0%$50.88+610.5%-83.6%$78.93MN/A-1.5340Positive NewsTCRXTScan Therapeutics3.9372 of 5 stars$1.37+7.9%$8.50+520.4%-85.8%$77.53M$4.42M-1.29100Positive NewsInsider TradeIMABI-Mab3.1896 of 5 stars$0.95+7.4%$5.50+482.0%-46.4%$77.02M$3.27M0.00380News CoverageJMACMaxpro Capital AcquisitionN/A$5.68flatN/A+1,580.3%$76.27MN/A0.002,021Gap UpINZYInozyme Pharma2.8857 of 5 stars$1.18+2.6%$14.63+1,139.4%-16.0%$76.18MN/A-0.7650CRBUCaribou Biosciences2.7545 of 5 stars$0.82+5.7%$9.33+1,040.9%-67.2%$76.09M$9.99M-0.50100 Related Companies and Tools Related Companies Invizyne Technologies Alternatives OncoCyte Alternatives Adagene Alternatives CervoMed Alternatives Corbus Pharmaceuticals Alternatives TScan Therapeutics Alternatives I-Mab Alternatives Maxpro Capital Acquisition Alternatives Inozyme Pharma Alternatives Caribou Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPA Stock Free IPA Stock Alerts